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Key Points
• Endothelial-restricted
complement activation occurs
in aHUS, and clinical
remission relies on efficient
endothelial complement
inhibition.
• Ex vivo serum-induced
endothelial C5b-9 deposits
are a sensitive tool to monitor
complement activation and
eculizumab effectiveness in
aHUS.
Atypical hemolytic-uremic syndrome (aHUS) is associated with genetic complement
abnormalities/anti–complement factor H antibodies, which paved theway to treatmentwith
eculizumab. We studied 44 aHUS patients and their relatives to (1) test new assays of
complement activation, (2) verify whether such abnormality occurs also in unaffected
mutation carriers, and (3) search for a tool for eculizumab titration. An abnormal circulating
complement profile (low C3, high C5a, or SC5b-9) was found in 47% to 64% of patients,
irrespective of disease phase. Acute aHUS serum, but not serum from remission, caused
wider C3 and C5b-9 deposits than control serum on unstimulated human microvascular
endothelial cells (HMEC-1). In adenosine 59-diphosphate–activated HMEC-1, also sera
from 84% and 100% of patients in remission, and from all unaffected mutation carriers,
induced excessive C3 and C5b-9 deposits. At variance, in most patients with C3
glomerulopathies/immune complex-associated membranoproliferative glomerulonephri-
tis, serum-induced endothelial C5b-9 deposits were normal. In 8 eculizumab-treated
aHUS patients, C3/SC5b-9 circulating levels did not change posteculizumab, whereas
serum-induced endothelial C5b-9 deposits normalized after treatment, paralleled or even
preceded remission, and guided drug dosing and timing. These results point to efficient
complement inhibition on endothelium for aHUS treatment. C5b-9 endothelial depositsmight helpmonitor eculizumabeffectiveness,
avoid drug overexposure, and save money considering the extremely high cost of the drug. (Blood. 2014;124(11):1715-1726)
Introduction
Atypical hemolytic-uremic syndrome (aHUS) consists of micro-
angiopathic hemolytic anemia, thrombocytopenia, and renal failure.1
Mutations in genes encoding complement factor H (CFH),
I (CFI), andB (CFB);membrane-cofactor protein (MCP); complement
C3 and thrombomodulin (THBD); and anti-CFH autoantibodies
(www.fh-hus.org)1-6 have been found in about 50% to 60% of
patients with aHUS, underscoring the importance of uncontrolled
complement activation in this devastating disease. Incomplete pene-
trance of aHUShas been reported inmutation carriers, indicating that
complement genemutations confer predisposition to develop aHUS,
with additional hits necessary for disease manifestation.1,7
Speciﬁc and sensitive markers of complement activation in aHUS
are lacking. C3 serum levels are of limited prognostic signiﬁcance.
Indeed, reduced C3 levels have been found in only 30% to 50%
of patients with mutations in CFH, MCP, CFI, and THBD or with
anti-CFH antibodies.2 An exception is represented by patients
with C3 or CFB mutations who mostly (70% to 100%) present with
hypocomplementemia. Mutant CFH, MCP, CFI, and THBD cannot
fully regulate the alternative complement pathway (AP) on endothelial
cells, as documented by in vitro tests.1,8,9 By contrast, aHUS-associated
mutant proteins effectively regulate complement in ﬂuid phase, which
would explain the normal or near-normal circulating C3 levels inmany
mutation carriers. Gain-of-function mutations of CFB and C3 form
a C3 convertase resistant to decay by endothelial cell regulators.3,4,9
These ﬁndings suggested that aHUS is a disease of unrestricted
endothelial complement activation, which eventually causes renal
microvascular thrombosis.1 In vivo evidence of the above pathogenetic
hypothesis came fromﬁndings that transgenicmice expressing amutant
Submitted February 25, 2014; accepted July 1, 2014. Prepublished online as
Blood First Edition paper, July 18, 2014; DOI 10.1182/blood-2014-02-558296.
M.N., M.G., and S.G. contributed equally to this study.
Presented in part at the 13th European Meeting on Complement in Human
Disease, Leiden, The Netherlands, August 21-24, 2011, and at the 24th
International Complement Workshop, Crete, Greece, October 10-15, 2012.
The online version of this article contains a data supplement.
There is an Inside Blood Commentary on this article in this issue.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked “advertisement” in accordance with 18 USC section 1734.
© 2014 by The American Society of Hematology
BLOOD, 11 SEPTEMBER 2014 x VOLUME 124, NUMBER 11 1715
CFH lacking surface-recognition domains develop spontaneous
aHUS.10 Interestingly, in thismousemodel, complementC5deﬁciency
protected from thrombotic microangiopathy, suggesting a critical role
ofC5 in aHUS.11 This represented a strong rationale for use of the anti-C5
humanizedmonoclonal antibody eculizumab in aHUS.12,13 This drug, by
blockade of C5 cleavage, protected frommicrovascular thrombosis
and radically improved the outcome of aHUS.13-15 However, how to
titrate anti-C5 treatment in clinical practice has not been addressed so far.
This study was designed in patients with aHUS and their rela-
tives with the aims to (1) test new sensitive assays of complement
activation at the endothelial cell level in aHUS patients, (2) clarify
whether unaffected relatives carrying complement gene mutations
show impaired complement regulation on endothelium, and (3)
search for a tool for monitoring and/or titrating anti-C5 treatment in
clinical practice, taking into account that complement activation
occurs on endothelium and not in ﬂuid phase.
By speciﬁc ex vivo assays, we demonstrate that aHUS patients
with or without identiﬁed complement gene mutations or anti-CFH
antibodies consistently and chronically activate complement on
endothelium. Also, unaffected gene mutation carriers show dysregu-
lated complement activation at the endothelial level. Finally, we
document that the level of C5 blockade on endothelium found in our
ex vivo test predicts clinical effectiveness of eculizumab in vivo and
could guide drug dosing and timing. This topic has particular clinical
relevance not only given the impressive therapeutic potential of
eculizumab13 but also taking into consideration that the cost of this
drug is so high that even in high-income countries, public health
systems and private insurances tend to limit eculizumab use.16,17
Methods
Study participants
aHUS was diagnosed in cases reported to have one or more episodes of
nonimmune hemolytic anemia, thrombocytopenia, and renal impairment
(details about disease diagnosis and deﬁnitions of acute disease and remission
are provided in supplemental “Methods” available at the Blood Web site).1
Patients in whom HUS was associated with Shiga toxin–producing bacteria
were excluded.
Among patients of the International Registry of HUS/thrombotic
thrombocytopenia purpura (TTP)2 with mutations in CFH, CFI, C3, and
CFB (encoding circulating complement proteins) or anti-CFH antibodies,
or without mutations in known genes, who consented to participate in this
study (36 patients [supplemental Table 1], plus 8 treated with eculizumab)
were enrolled. Seven consenting healthy relatives carrying complement gene
mutations and 7 healthy relatives without mutations/anti-CFH antibodies were
also studied. This study did not include patients with mutations in DGKE,
recently identiﬁed in infantile recessive aHUS,18 or in MCP or THBD, all
encoding intracellular or transmembrane proteins.
Fifteen patients with C3 glomerulopathies (C3G)19 or immune complex–
associated membranoproliferative glomerulonephritis (IC-MPGN; supple-
mental “Methods” and supplemental Table 2), all diseases associated with
complement activation in ﬂuid phase,20,21 were also studied.
Controls were 30 healthy subjects age and sex matched with patients.
The protocol was approved by the ethical committee of the Azienda Sanitaria
Locale Bergamo, Italy. Participants or their legal guardians provided written
informed consent in accordance with the Declaration of Helsinki.
Study assessments
Methods used for measuring serum and plasma complement proﬁle;
complement deposits in kidney biopsy specimens (available for 5 patients);
the effect of incubationwith serum frompatients, healthy relatives, and controls
on complement deposits on cultured human microvascular endothelial cells
(HMEC-1); and statistical analyses are detailed in supplemental “Methods.”
Results
Circulating complement profile in patients with aHUS with or
without mutations
During the acute phase, we found lower than normal serumC3 levels
in 56% of patients (Table 1). Lower than normal serum C3 levels
were found in 47% of patients in remission (Table 1).
During the acutephase, plasma levels of the anaphylatoxinC5aand
of the cytolytically inactive terminal-complement complex (SC5b-9)
were higher than normal in 47% and 53% of patients, respectively. At
remission, increased C5a and SC59b-9 plasma levels were found in
58% and 64% of patients, respectively (Table 1).
No signiﬁcant differencewas found in the prevalence of circulating
complement abnormalities among patients with or without comple-
ment gene mutations/anti-CFH antibodies (Table 1) either during the
acute phase or at remission.
Renal complement deposition profile in aHUS patients with or
without mutations
As microangiopathic lesions of aHUS mainly localize in the kidney
microcirculation, we looked at markers of complement activation in
kidney biopsy specimens taken during the acute phase from 5 out of
44 patients (CFHmutations, n5 1;C3mutation, n5 1;CFImutation,
n5 1; no mutation, n5 2). Strong immunostaining for C3 (Figure 1A)
and C9 neoantigen (Figure 1B-D), which reﬂects C5b-9 formation,
was found in glomeruli of all patients. In small arteries, strong endo-
thelial C3 reactivity was observed (Figure 1E-F), whereas C9 staining
mainly displayed a subendothelial localization (Figure 1G). C3 and
C9 kidney deposits were found irrespective of whether the patients
had increased (Figure 1C) or normal plasma SC5b-9 (Figure 1A).
Serum from aHUS patients with or without mutations or
anti-CFH antibodies induced C3 and C5b-9 deposition on
microvascular endothelial cells
To ﬁnd a sensitive test of complement activation on endothelium,
resting or adenosine 59-diphosphate (ADP)-activated conﬂuent
HMEC-1 were incubated for 4 hours with serum (diluted 1:2 in the
test medium Hanks balanced salt solution with bovine serum
albumin; supplemental “Methods”) from the 36 aHUS patients not
treated with eculizumab (eculizumab-treated patients were studied
apart [see below]), with or without identiﬁed complement gene
mutations/anti-CFH antibodies. Thereafter, HMEC-1 were stained
with anti-human C3c or anti-human C5b-9 antibodies and comple-
ment deposits were analyzed by confocal microscopy (supplemental
“Methods”). Supplemental Figure 1 shows a schematic representation
of ex vivo studies of HMEC-1. Seven of the 36 patients were studied
bothduring the acutephase and in remission, 7 only in the acutephase,
and 22 only in remission (Table 2). Serum from patients with acute
aHUS, but not serum from most patients at remission, caused more
C3 and/or C5b-9 deposition on resting HMEC-1 than control serum
(Figure 2A-B and Table 2). On HMEC-1 pre-exposed to ADP, all
acute aHUS sera and most aHUS sera taken in remission (sensitivity
84%) induced more C3 deposition than control sera (Table 2,
Figure 2A,C, and D, and supplemental Table 1). ADP was used to
mimic an activated/perturbed endothelium resulting in exocytosis of
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P-selectin (supplemental Figure 2), an adhesive molecule that can
bind and activate C3.22,23 The same results were obtained with
thrombin- or lipopolysaccharide-activated HMEC-1 (supplemental
Figure 3).
C3 deposits were blocked by adding AP inhibitors to serum
(Figure 3A-B). This ﬁnding, together with lack of C4 or immuno-
globulin G staining on ADP-activated HMEC-1 exposed to aHUS
serum (supplemental Figure 4), indicates selective activation of
the AP.
Sera from all patients either in acute phase or in remission,
including those with normal SC5b-9 plasma levels, caused signiﬁ-
cantly higher C5b-9 deposits onADP-activated HMEC-1 than control
sera run in parallel (Table 2; Figure 2B,E,F; and supplemental
Table1), documenting thehigher sensitivity (100%)of this exvivoassay
vs elevated plasma SC5b-9 levels (Table 2) in detecting complement
dysregulation in aHUS. By testing different serum dilutions, we found
that the effect of aHUS serum on C5b-9 deposits was dose dependent
(supplemental Figure 5). C5b-9 deposits were prevented by an anti-C5
minibody, by eculizumab (Soliris, Alexion Pharmaceuticals), or by
an anti-C7 antibody added to aHUS serum, supporting the speciﬁcity
of the anti–C5b-9 antibody used for the staining (Figure 3C-D).
Concordance correlation test of C5b-9 deposits induced on ADP-
activated HMEC-1 by serum from 8 patients tested twice in different
experiments revealed a coefﬁcient of 0.879, documenting the good
reproducibility of the test (supplemental Figure 6).
aHUSserum-inducedC5b-9 deposits onADP-activatedHMEC-1
(% of controls) did not correlate with SC5b-9 levels in the same sera
or in plasma (supplemental “Results” and supplemental Figure 7),
which would exclude that endothelial C5b-9 deposits derived from
preformed serum SC5b-9.
To evaluate whether the test speciﬁcally picked out endothelial-
restricted complement activation of aHUS, additional experiments
were done with sera from 15 patients with C3G or IC-MPGN and
AP complement activation in the ﬂuid phase.20,21 In all but one
patient with C3G/IC-MPGN, serum-induced C5b-9 deposits on
ADP-activated HMEC-1 did not differ between patients and healthy
controls (supplemental Table 2).
Serum from unaffected carriers of complement gene mutations
induced C3 and C5b-9 deposition on microvascular
endothelial cells
To evaluate whether C3 and C5b-9 deposition was the consequence
of aHUS disease status or whether mutations per se predisposed to
complement dysregulation on endothelium, serum from 7 unaffected
relatives (supplemental Figure 1) that carriedCFH (n54),CFI (n51),
or C3 (n5 1) mutations or a CFHR1/CFH hybrid gene (n5 1)24 was
tested. Serum from unaffected mutation carriers induced more C3 and
C5b-9 deposition than control serum on ADP-activated HMEC-1
(Figure 4A-C). At variance, serum from 7 unaffected relatives without
Figure 1. Immunohistochemical analysis of C3 and C9 (C5b-9) staining in kidney biopsy specimens from aHUS patients. Representative results are shown. (A)
C3 deposits with main endothelial localization in a glomerulus from a patient with a CFI mutation and normal SC5b-9 plasma levels. (B) C9 staining restricted to hilar area
in a glomerulus from a patient with a C3 mutation. (C) Diffuse C9 deposits in 2 glomeruli with marked ischemic injury from a patient with CFH mutation and increased
SC5b-9 levels. (D) C9 deposits in glomeruli from a patient without mutations/anti-CFH antibodies. (E-F) endothelial C3 staining in arterioles from patients with CFH (E)
and CFI (F) mutations. (G) Subendothelial localization of C9 staining in an arteriole from a patient with a CFH mutation and normal SC5b-9 level. (H) Control section
(healthy portion of nephrectomy for cancer, C9 staining). Original magnification 3400, counterstaining with hematoxylin.
Table 1. Circulating complement profile in aHUS patients
Complement parameters Disease phase Overall Mutations or anti-CFH Ab No mutations
Reduced C3 serum levels (83-180 mg/dL)* Acute† 10 (18) 5 (9) 5 (9)
Remission‡ 15 (32) 11 (25) 4 (7)
Increased C5a plasma levels (1.9-13.1 ng/mL)* Acute† 9 (19) 3 (10) 6 (9)
Remission‡ 21 (36) 15 (27) 6 (9)
Increased SC5b-9 plasma levels (127-400 ng/mL)* Acute† 10 (19) 4 (10) 6 (9)
Remission‡ 23 (36) 20 (27) 3 (9)
Ab, antibody.
*Limits of normal ranges (as defined in supplemental “Methods”). In parentheses are the numbers of patients for whom data were available, and outside the parentheses
are the numbers of patients with reduced C3 or increased C5a or SC5b-9 levels.
†One patient was receiving eculizumab at the time of the test.
‡Eight patients were receiving eculizumab at the time of the tests.
BLOOD, 11 SEPTEMBER 2014 x VOLUME 124, NUMBER 11 aHUS: MONITORING COMPLEMENT ACTIVATION AND THERAPY 1717
mutations induced C5b-9 deposition comparable to control serum
(Figure 4B-C).
In aHUS patients, eculizumab normalized ex vivo complement
deposition on ADP-activated endothelial cells and induced
stable remission
We then retrospectively evaluated the effect of eculizumab treatment
on serum-induced C5b-9 deposits in ADP-activated HMEC-1 in 4
patients (cases 1-4; Table 3) studied both during the acute phase
before eculizumab and in stable remission under chronic eculizumab
(supplemental Figure 1).
The 4 patients are a 20-year-old woman with familial aHUS
and a hybrid CFHR1/CFH gene24 (case 1, the daughter of patient
23), a 20-year-old woman with sporadic aHUS and a heterozy-
gous p.L433SCFBmutation (case 2), a 1-year-old infant (case 3),
and a 45-year-old man (case 4), both without identiﬁedmutations/
anti-CFH antibodies. Cases 1 to 4 started eculizumab treatment
(cases 1, 2, and 4 received 4 infusions 900 mg weekly, then
Table 2. Complement activation markers in aHUS patients
Patients
Mutations or
anti-CFH Ab
Complement parameters Endothelial complement deposits
Serum C3
(83-180 mg/dL)*
Serum C4
(10-40 mg/dL)*
Plasma C5a
(1.9-13.1 ng/mL)*
Plasma SC5b-9
(127-400 ng/mL)*
C3 deposits
(% of control)
C5b-9 deposits
(% of control)
Resting ADP-activated Resting ADP-activated
Acute
Patient 1 CFH-R1210C 122 38 16.1 375 450%† 286%† 340%† 309%†
Patient 2 CFH-R1210C n.d. n.d. 7.3 1160 n.d. n.d. 441%† 609%†
Patient 3 CFH-R78G 55 23 7.8 381 n.d. n.d. 285%† 306%†
Patient 4 Anti-CFH Ab 58 10 10 653 489%† 288%† 371%† 599%†
Patient 5 No 84 25 5 220 301%† 297%† 722%† 857%†
Patient 6 No 108 28.8 n.a. n.a. n.d. n.d. 787%† 577%†
Patient 7 No 51 11 1.8 69 n.d. n.d. n.d. 1055%†
Patient 8 No 89 22 31.1 335 n.d. n.d. 1044%† 1087%†
Patient 9 No n.d. n.d. 49.8 933 n.d. n.d. 1509%† 1060%†
Patient 10 No 82 13 61.5 541 n.d. n.d. 470%† n.d.
Patient 11 No 58 18 61 1432 n.d. n.d. 167% n.d.
Patient 12 No n.d. n.d. n.a. n.a. n.d. n.d. 650%† n.d.
Patient 13 No n.d. n.d. 21.2 713 n.d. n.d. 476%† n.d.
Patient 14 No 103 18.7 n.a. n.a. n.d. n.d. 881%† n.d.
Remission
Patient 1 CFH-R1210C 108 30 31.2 233 213% 240%† 108% 187%†
Patient 2 CFH-R1210C n.d. n.d. n.a. n.a. n.d. n.d. 94% 644%†
Patient 3 CFH-R78G 51 17 12.2 725 n.d. 86% 86% 195%†
Patient 15 CFH-S1191L 109 36 14.9 656 n.d. 234%† n.d. 468%†
Patient 16 CFH-S1191L 115 21 8.3 447 n.d. 258%† n.d. 504%†
Patient 17 CFH-S1191L 51 33 14.5 178 n.d. 387%† n.d. 590%†
Patient 18 CFH-E1172X 51 26 3.6 476 n.d. 167%† n.d. 244%†
Patient 19 CFH-R1215G 73 24 16 655 n.d. 167%† n.d. 242%†
Patient 20 CFH-1183-1194 dup n.d. n.d. 10.7 342 n.d. 287%† n.d. 351%†
Patient 21 CFH-N516K 65 40 29.8 905 n.d. 112% n.d. 255%†
Patient 22 CFH-G1011Vfs4X 80 22 14.8 802 n.d. 149% n.d. 158%†
Patient 23 CFHR1/CFH hybrid n.d. n.d. 29.6 236 n.d. n.d. n.d. 605%†
Patient 24 CFI-G261D 136 38 11.3 1100 n.d. 342%† n.d. 209%†
Patient 25 CFI-1340T/G424D 136 72 21.2 719 n.d. 341%† n.d. 326%†
Patient 26 CFI-P50A 125 41 18.6 676 n.d. 482%† n.d. 250%†
Patient 27 CFI-1357M 94 21 8.8 515 n.d. 291%† n.d. 520%†
Patient 28 C3-K1029M 55 29 13.3 348 n.d. 294%† n.d. 253%†
Patient 29 C3-T140R 82 26 8.6 1052 n.d. 151%† n.d. 213%†
Patient 30 C3-S1041R 86 11 7.2 444 n.d. 311%† n.d. 171%†
Patient 31 CFB-R138W 65 15 9.5 455 n.d. 223%† n.d. 182%†
Patient 4 Anti-CFH Ab 149 38 8.1 591 93% 344%† 79% 516%†
Patient 32 Anti-CFH Ab 75 14 24.9 1206 n.d. 99% n.d. 316%†
Patient 5 No n.d. n.d. 3 183 112% 302%† 157% 504%†
Patient 6 No 120 20 14.7 280 n.d. n.d. 104% 431%†
Patient 7 No n.d. n.d. 2.5 117 n.d. n.d. n.d. 937%†
Patient 33 No 79 28 31.1 1780 n.d. 283%† n.d. 282%†
Patient 34 No 63 28 13.5 209 n.d. 343%† n.d. 567%†
Patient 35 No 204 58 15.6 850 n.d. 286%† n.d. 468%†
Patient 36 No 57 32 16.8 1490 n.d. 450%† n.d. 504%†
Patients studied both during the acute phase and at remission are in bold.
Ab, antibody; n.a. sample not available; n.d. not done.
*Limits of normal ranges (as defined in supplemental “Methods”).
†P , .05 vs control (statistical comparisons were made for each patient by comparing deposits in pixel2 recorded in the 15 fields analyzed for the patient and for the
corresponding control run in parallel, as detailed in supplemental “Methods” and in supplemental Table 1).
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Figure 2. aHUS serum induces C3 and C5b-9 deposition on microvascular endothelial cells (HMEC-1). (A-B) Endothelial surface area covered by C3 (A) or C5b-9 (B)
staining after incubation of unstimulated (resting) or ADP-activated HMEC-1 for 4 hr with serum (diluted 1:2 in test medium) from healthy subjects (Ctr; n 5 4) or from aHUS
patients (C3: n 5 3, 1 with CFH mutation, 1 with anti-CFH antibodies, and 1 without identified mutations/anti-CFH antibodies; C5b-9: n 5 7, 3 with CFH mutation, 1 with anti-
CFH antibodies, and 3 without identified mutations/anti-CFH antibodies) studied both during the acute phase of the disease (Acute) and at remission (Rem) or from 7 aHUS
patients studied in the acute phase only (panel B, C5b-9, acute only, all without identified mutations/anti-CFH antibodies). Data are mean 6 standard error (SE). ^P , .01 vs
control resting; °°P , .01, °°°P , .05 vs control ADP-activated; &P , .001, &&P , .01, &&&P , .05 vs remission resting. (C,E) Endothelial surface area covered by C3 (C) or
C5b-9 (E) staining after incubation of ADP-activated HMEC-1 for 4 hr with serum from aHUS patients studied in remission (C3: n5 25, CFHmutations: n5 10; CFImutations:
n 5 4; C3 mutations: n 5 3; CFB mutation: n 5 1; anti-CFH antibodies: n 5 2; without identified mutations/anti-CFH antibodies: n 5 5 ; C5b-9: n 5 29, CFH mutations or
CFHR1/CFH hybrid gene: n 5 12; anti-CFH antibodies: n 5 2; CFI mutations: n 5 4; C3 mutations: n 5 3; CFB mutation: n 5 1; without identified mutations/anti-CFH
antibodies: n 5 7), in the presence or not of the complement inhibitor sCR1 (150 mg/mL). Range of deposits induced by control serum (mean 6 SE): dotted horizontal areas.
(D,F) Representative confocal microscopy images of C3 (D, in green) or C5b-9 (F, in green) staining of ADP-activated HMEC-1 exposed to serum from an healthy subject (Ctr) or
an aHUS patient in remission (aHUS) (original magnification 3400). Additional images are shown in supplemental Figure 11. Data are mean 6 SE. °P , .001, °°°P , .05 vs
control serum; *P , .001, **P , .01 vs aHUS serum without sCR1. Both C3 and C5b-9 deposits were prevented by addition of sCR1 (an inhibitor of all the 3 complement
pathways) to patient serum, indicating that the staining was specifically related to complement activation products. mut, mutation.
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1200 mg fortnightly; case 3 received 2 infusions 300 mg weekly,
then 300 mg every 2-3 weeks) at 13, 8, 8, and 30 days after
aHUS onset, respectively. Details of familial and clinical history,
genetic analysis, and eculizumab treatment are provided in supple-
mental “Results.”
In the 4 cases, serum taken in the acute phase before eculizumab
caused intenseC5b-9depositiononADP-activatedHMEC-1 (Table 3),
consistent with complement dysregulation at endothelial level, while
plasmaSC5b-9was increased in2out of 4 cases (Table 3).Eculizumab-
induced disease remissionwas accompanied by normalization of ex
vivoC5b-9 deposits (Table 3). At that time, plasmaSC5b-9 levels were
higher than normal in 2 out of 4 cases and complement hemolytic
activity (CH50) was 5, 11, 46, and 4 U Eq/mL in cases 1, 2, 3, and 4,
respectively.
In aHUS patients, prospective ex vivo endothelial complement
deposition evaluation was instrumental to titrate
eculizumab dosage
Case 5. A 7-year-old child with familial aHUS (supplemental
Figure 8) and a heterozygousCFHmutation (p.S1191L)25manifested
aHUS at 6 months. Despite chronic plasma therapy, the child had
12 relapses and progressed to end-stage renal disease (Figure 5). At
5 years, the child received a kidney transplant under eculizumab
prophylaxis to prevent posttransplant recurrence.26 Before transplant
and eculizumab treatment, he had 237 000 platelets/mL. Serum taken
at this point caused intense C5b-9 deposition on ADP-activated
HMEC-1,whereas plasma SC5b-9was normal (Figure 5 and Table 3).
The posttransplant course was uneventful until months 14 to 15,
when he developed a drop in platelets with slightly increased LDH
despite the low CH50 (3 U Eq/mL) measured 8 days after the former
eculizumab infusion indicated almost complete circulating C5
inhibition (Table 3). Serum taken at this point caused higher C5b-9
deposits on ADP-activated HMEC-1 than control serum (Figure 5
and Table 3), whereas SC5b-9 plasma levels were normal. Higher
than normal endothelial C5b-9 deposits suggested that the
eculizumab dose was not enough to completely block comple-
ment activation on endothelium. The eculizumab dose was doubled
(from 300 to 600 mg every other week), which resulted in prompt
normalization of endothelial C5b-9 deposits. Platelet count in-
creased, without fully normalizing (Table 3). After 6 months of
600 mg eculizumab, endothelial C5b-9 deposits were still normal,
Figure 3. Effect of complement inhibitors on aHUS serum-induced C3 and C5b-9 deposition on ADP-activated HMEC-1. (A-B) Effect of selective inhibitors of the
alternative pathway of complement, an anti-CFB antibody (anti-CFB, 150 mg/mL), the CR2-FH fusion protein (CR2-FH, 150 mg/mL and 300 mg/mL), and a CFH concentrate
from human plasma (CFH conc, at levels comparable to those of normal human serum, 230 mg/mL) on C3 deposition induced on ADP-activated HMEC-1 by serum from 3
patients with aHUS and CFH mutations studied in remission in 3 independent experiments. (C) Effect of terminal complement pathway inhibitors, an anti-C5 minibody (anti-
C5, 135 mg/mL), or an anti-C7 goat polyclonal antibody (anti-C7, 350 mg/mL) or eculizumab (Ecu, 150 mg/ml) on C5b-9 deposition induced on ADP-activated HMEC-1 by
serum of patients with aHUS studied in remission. Data are from 3 different experiments in 3 patients (CFH mutations, n 5 2; C3 mutation, n 5 1) and 3 controls. (D) Effect of
3 doses of eculizumab (Ecu; 100, 50, or 25 mg/mL) on C5b-9 deposition on ADP-activated HMEC-1 induced by serum of patients with aHUS studied in the acute phase before
any treatment. Data are from 3 different experiments in 3 patients (without mutations or anti-CFH antibodies) and 3 controls. Data are mean 6 SE. °P , .001, °°P , .01,
°°°P , .05 vs control serum; *P , .001, **P , .01, ***P , .05 vs aHUS serum untreated. Control range: dotted horizontal areas. ctr, control.
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and platelets and LDH normalized (Figure 5 and Table 3). SC5b-9
and CH50 levels measured in parallel did not differ from values
obtained under 300 mg eculizumab (Figure 5 and Table 3).
These ﬁndings can be interpreted as to suggest that although
circulating C5 activation was well controlled by both eculizumab
doses, only the highest dose efﬁciently prevented C5 endothelial
activation. Additional clinical and familial information are provided
in supplemental “Results.”
Case 6. Sporadic acute aHUS was diagnosed in a 8 year-old
boy with a heterozygous rare variant in C3 gene (p.K633R). He had
a medical history of hemolytic crisis and epistaxis diagnosed as
glucose-6-phosphate dehydrogenase deﬁciency. Serum taken at this
point caused intense C5b-9 deposition on ADP-activated HMEC-1,
whereas plasma SC5b-9 was normal (Table 3). The patient was
treated with erythrocyte transfusions and plasma exchange. Because
of worsening of renal function and oliguria, eculizumab was started
(600 mg weekly for 2 infusions and then every 12/14 days), with
progressive regression of neurologic impairment and respiratory
failure. During the initial course of the therapy, the boy suffered
from 2 hypertensive crises associated with pulmonary edema,
an increase in serum creatinine levels, and persistent hemolytic
anemia (Table 3). SC5b-9 levels were normal and CH50 very low
(1UEq/mL;Table3). Serum-inducedC5b-9deposits onADP-activated
HMEC-1 did not completely normalize (Table 3). Antihypertensive
polytherapy was given, and the eculizumab dose was increased to
900 mg, obtaining blood pressure stabilization, progressive normal-
izationof renal function, and complete normalizationof platelet counts,
LDH, and serum-induced C5b-9 deposits on ADP-activated HMEC-1
(Table 3), whereas SC5b-9 plasma levels were higher than normal
and CH50 was detectable at 11 U Eq/mL (Table 3). Additional
clinical information is provided in supplemental “Results.”
In aHUS patients, a prospective ex vivo endothelial complement
deposition assay supported eculizumab dose spacing
Case 7. Amale with a heterozygous CFHmutation (p.R1210C)27
manifested aHUS at 35 years. Intense serum-induced endothelial
C5b-9 deposits were observed during the acute phase (Figure 6 and
Figure 4. Serum from healthy carriers of complement gene mutations induces C3 and C5b-9 deposition on ADP-activated microvascular endothelial cells (HMEC-1).
(A-B) Endothelial surface area covered by C3 (A) or C5b-9 (B) staining after incubation of ADP-activated HMEC-1 for 4 hr with serum (diluted 1:2 in test medium) from aHUS patients
(C3 deposits: n5 6, 4 with CFHmutations, 1 with C3mutation, and 1 with CFImutation; C5b-9 deposits: n5 7, 4 with CFHmutations, 1 with C3mutation, 1 with CFImutation, and 1
with CFHR1/CFH hybrid gene) or from their healthy relatives carrying the same mutations (C3 deposits: n 5 5, 3 with CFH mutation, 1 with C3 mutation, and 1 with CFI
mutation; C5b-9 deposits: n 5 6, 3 with CFH mutation, 1 with C3 mutation, 1 with CFI mutation, and 1 with CFHR1/CFH hybrid gene) in the presence or not of the complement
inhibitor sCR1 (150 mg/mL) or from 7 healthy relatives without mutations (C5b-9 deposits). Control serum range: dotted horizontal areas. Data are mean6 SE. °P, .001, °°P, .01,
vs control serum; *P , .001, **P , .01 vs aHUS patients without sCR1; §P , .001 vs mutation carriers without sCR1; #P , .01 vs carrier; &P , .001, &&P , .01 vs no carrier. (C)
Data of plasma SC5b-9 levels and serum-induced C3 and C5b-9 deposition on ADP-activated HMEC-1 in unaffected relatives carrying complement gene mutations (healthy mutation
carrier, n5 7) and unaffected relatives without mutations (only C5b-9, healthy no carrier, n5 7). °Limits of normal ranges (as defined in supplemental “Methods”). *P, .05 vs control
serum (statistical comparisons were made for each relative by comparing deposits in pixel2 recorded in 15 fields analyzed for the relative and for the corresponding control
run in parallel, as detailed in supplemental “Methods”). £: Serum-induced C3 or C5b-9 deposits on ADP-activated HMEC-1. mut, mutation; n.a., not available; n.d., not done.
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Table 3). Plasma SC5b-9 levels were slightly higher than normal
(Table 3). He received 9 eculizumab infusions (600-1200mg) during
the ﬁrst month and then 1200mg fortnightly (Figure 6). Twomonths
later, renal function improved and hemodialysis was stopped.
Clinical remission was accompanied by normalization of ex vivo
C5b-9 deposits on ADP-activated HMEC-1, whereas plasma SC5b-9
remained higher than normal and CH50 was 10 U Eq/mL (Figure 6
and Table 3). The following 18 months were uneventful, and
eculizumab treatment was spaced every 3 weeks. At that time, a check
of complement activation parameters 21 days after eculizumab (before
the subsequent dose) revealed normal serum-induced C5b-9 deposits
on ADP-activated HMEC-1 and SC5b-9 levels, despite a CH50
increase to 32 U Eq/mL (Figure 6 and Table 3). The treatment regimen
wasmaintained. At the last follow-up, 1 year after eculizumab spacing,
the patient was in stable condition. Additional clinical information is in
supplemental “Results.”
Case 8. Awomanwith a heterozygousCFImutation (p.R187Q)
manifested recurrent aHUS since 34 years of age. At admission, she
showed worsening renal function, thrombocytopenia and hemolysis,
and higher than normal serum-induced C5b-9 deposits on ADP-
activated HMEC-1 and SC5b-9 plasma levels (Table 3). The woman
was treatedwith 17 plasma exchanges and immunoglobulinswithout
beneﬁt. Eculizumab was given (900 mg weekly, 5 infusions),
obtaining hematologic normalization and improvement of renal
function. The patient was discharged under 1200 mg eculizumab
fortnightly, with normal serum-induced C5b-9 deposits, almost
normal plasma SC5b-9, and low CH50 (Table 3). Eighteen months
later, the patient was in stable condition and eculizumab was spaced
to 1200 mg once a month. At this time point, induced C5b-9
deposits on ADP-activated HMEC-1 by serum taken 1 month after
eculizumab (before the subsequent dose) and SC5b-9 plasma
levels were completely normal, whereas CH50 increased to
22 U Eq/mL (Table 3). The monthly eculizumab regimen was
maintained, without sign of disease reactivation in the following
12 months. Additional clinical information is provided in supple-
mental “Results.”
Table 3. Complement profile in eculizumab-treated aHUS patients
Case
Mutation or
anti-CFH Ab
Disease phase
treatment
Clinical parameters* Complement parameters
Platelets
(150-400 3
103/mL)
LDH
(266-500 IU/L)
Hemoglobin
(14-18 g/dL)
Serum
creatinine
(0.55-1.25
mg/dL)
Serum C3
(83-180 mg/dL)†
Plasma
SC5b-9 (127-400
Eq/mL)†
Serum
CH50 (79-187 U
Eq/mL)†
C5b-9
deposits‡
(% of
control)
1 CFHR1/CFH Acute (pre-Ecu) 111 000 2000 5.1 6 79 329 227 309§
Hybrid gene 9 d post-Ecu
1200 mg
318 000 741 12.6 1.7 91 533 5 71
2 CFB -L433S Acute (pre-Ecu) 121 000 2011 5.5 27 77 156 100 1019§
14 d post-Ecu
1200 mg
280 000 357 12.9 1.22 65 967 11 106
3 No mutations Acute (pre-Ecu) 19 000 2373 9.2 1.9 50 411 142 478§
No anti-CFH
Ab
21 d post-Ecu
300 mg
564 000 n.d. 12.5 0.6 76 116 46 105
4 No mutations Acute (pre-Ecu) 107 000 768 9.6 15.2 78 556 45 439§
No anti-CFH
Ab
14 d post-Ecu
1200 mg
161 000 342 11.7 4.77 88 260 4 59
5 CFH-S1191L Remission
(pre-Ecu)
237 000 576 10.9 8.91 93 121 72 298§
8 d post-Ecu
300 mg
67 000 560 13.5 0.52 103 195 3 152§
12 d post-Ecu
600 mg
119 000 588 13.6 0.59 95 214 3 43
11 d post-Ecu
600 mg
225 000 493 12.6 0.5 n.d. 167 6 76
6 C3-K633R Acute (pre-Ecu) 39 000 5000 7.7 1.48 123 392 93 342§
6 d post-Ecu
600 mg
159 000 854 8.5 4.29 126 231 1 119
6 d post-Ecu
900 mg
232 000 473 11.5 1.5 n.d. 566 11 82
7 CFH-R1210C Acute (pre-Ecu) 46 000 1962 7 5.7 79 421 118 474§
14 d post-Ecu
1200 mg
277 000 336 11.9 1.4 89 505 10 102
21 d post-Ecu
1200 mg
307 000 264 12.2 1.2 83 231 32 75
8 CFI-R187Q Acute (pre-Ecu) 94 000 869 7.2 4.5 99 534 n.d. 177§
14 d post-Ecu
1200 mg
212 000 401 10.1 2 89 435 6 24
1 mo post-Ecu
1200 mg
185 000 434 11.6 1.93 85 298 22 92
Ab, antibody; Ecu, eculizumab; n.d. not done.
*Clinical data in the table are those recorded the same days when complement parameters were evaluated.
†Limits of normal ranges (as defined in supplemental “Methods”).
‡Serum-induced C5b-9 deposits on ADP-activated endothelial cells (HMEC-1).
§P , .01 vs control (serum from healthy subjects run in parallel, with 15 fields analyzed, as detailed in supplemental “Methods”).
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In the 8 cases, serum-induced C5b-9 deposits on ADP-activated
HMEC-1 during eculizumab treatment were lower (P , .001) than
pretreatment values, whereas no signiﬁcant change was observed
among pre- and posteculizumab levels of either serumC3 or plasma
SC5b-9 (supplemental Figure 9). Serum-induced endothelial
C5b-9 deposits (% of controls) under eculizumab treatment did not
correlate with platelet counts (r 5 0.009; supplemental Figure 10),
indicating that the ex vivo test is not just a surrogate of platelet count
measurement.
Discussion
Here, we document that circulating levels of C3, SC5b-9, and C5a are
normal in a substantial fraction of aHUS patients even during the acute
phase, which indicates that serum C3 and plasma SC5b-9 and C5a
are not suitable markers of complement activation in this disease. At
variance, all sera from aHUS patients induced abnormal C3 and/or
C5b-9 deposits onADP-activated endothelial cells ex vivo. The in vivo
counterparts of these ﬁndings are provided by intense glomerular and
arteriolar C3 and C9 staining in patient biopsy specimens. The
above ﬁndings conﬁrm previous in vitro studies with complement
mutant proteins, indicating that local complement activation on
endothelial cells rather than in ﬂuid phase plays a pathogenetic role
in aHUS.1,3,8,9,25
The pathogenetic role of complement in aHUS was eventually
conﬁrmed by clinical trials showing that eculizumab, by blockade of
C5 cleavage, protected frommicrovascular thrombosis and radically
improved the outcome of aHUS patients.13 However, a letter to The
New England Journal of Medicine raised a critique to the above
article,13 because “yet 24 to 30% of the study patients had no proven
genetic disease, and proof of ongoing complement activation was
lacking.”28 Theﬁnding here that sera frompatientswithout identiﬁed
mutations or anti-CFH antibodies induced more intense C3 and
C5b-9 deposits on ADP-activated HMEC-1 than control sera supports
the concept that there are still unrecognized genetic or acquired
complement abnormalities leading to aHUS. Previous studies have
described a simple hemolytic assay with sheep erythrocytes and
patient serum for detecting defects in the control of complement
activation on cellular surfaces.29,30 However, the sensitivity of the
hemolytic test appeared to be restricted to CFH-related HUS.29,30
Figure 5. Effect of eculizumab on clinical and complement parameters in case 5. Treatments, platelet count, plasma SC5b-9 levels, and serum-induced complement
deposition on ADP-activated HMEC-1 (by calculating HMEC-1 area covered by C5b-9 staining in pixel2) after incubation (4 hr) with serum (diluted 1:2 with test medium) from
case 5 taken immediately pretransplant before eculizumab treatment (pre-Ecu), at 15 months posttransplant after eculizumab treatment (post-Ecu, 300 or 600 mg), and
21 months posttransplant after eculizumab treatment (post-Ecu, 600 mg). Green arrow indicates eculizumab prophylaxis for kidney transplant. Black arrow indicates the time
of kidney transplant. Red arrows indicate times of sampling for plasma SC5b-9 and serum-induced ex vivo complement deposits. Data are mean 6 SE of 15 fields examined
for each sample. The horizontal rectangle shows range of endothelial C5b-9 deposits with control sera (mean6 SE). °P, .001, °°°P, .05 vs control serum; #P, .01 vs case
5 pre-Ecu; xxxP , .05 vs case 5, 8 days post-Ecu 300 mg.
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Of relevance, serum from aHUS patients studied in the acute
phase deposited complement both on resting and activated endothelial
cells, which would reﬂect a massive in vivo complement activation as
a consequence of both genetic defects and environmental triggers. At
variance, complement deposition by aHUS serum collected in
remission occurred only on activated endothelial cells. This ﬁnding
ﬁts with the “2-hit model” of aHUS: gene mutations predispose to
aHUS, but the disease develops only in concomitance with an
environmental trigger that perturbs microvascular endothelium.31
As multiple membrane-bound complement regulators bind to or are
expressed at endothelial surface, in the absence of inciting events, the
endothelium can control complement even when activity of one
regulator is reduced by gene mutations.32 However, due to defective
complement regulation, upon endothelial activation via diverse triggers
(infections, drugs, pregnancy, or ischemia/reperfusion), complement
products settle on endothelial cells and likely initiate the thrombotic
microangiopathy process.2 Thus, remission state is plausibly meta-
stable in patients with complement gene abnormalities, and any of the
above triggers may precipitate a relapse. In this regard, the ex vivo test
with resting endothelial cells shownhere could represent a biomarker of
disease burst in patients at risk of relapse either in the native kidneys or
after kidney transplantation.
It is well known that the penetrance of aHUS in carriers of
complement gene mutations is incomplete,1,2,4,5,7,27,33,34 and some
subjects never develop aHUS or manifest the disease very late in
adulthood. An epidemiologic study in familial cases reported that
penetrance of aHUS by age 45 years was 50% among carriers of gene
mutations.35Our results showing that serum fromunaffectedmutation
carriers also induced excessive C3 and C5b-9 deposits on ADP-
activated endothelial cells suggest that these subjects have
impaired complement regulation at the endothelial level and are
at disease risk, though prospective studies are needed to prove our
hypothesis.
Tanimoto et al,36 in another letter to The New England Journal of
Medicine on the report of eculizumab trials in aHUS,13 underlined
the need “to determine whether the terminal complement pathway is
adequately blocked.” The authors’ reply that “the lack of standard-
ization and validation of available complement assays currentlymakes
Figure 6. Effect of eculizumab on clinical and complement parameters in case 7. Treatments, platelet count, plasma SC5b-9 levels, and complement deposition on ADP-
activated HMEC-1 (by calculating HMEC-1 area covered by C5b-9 staining in pixel2) after 4-hr incubation with serum (diluted 1:2 in test medium) from case 7 taken during the
acute phase before start of eculizumab treatment (pre-Ecu) and in full remission (normal renal and hematologic parameters) after eculizumab (at the adult dose of 1200 mg
every 2 and 3 weeks; post-Ecu). Red arrows indicate times of sampling for plasma SC5b-9 and serum-induced ex vivo complement deposits. Green arrow: from this time, the
patient was treated with eculizumab every 3 weeks. Data are mean 6 SE of 15 fields examined for each sample. The horizontal rectangle shows range of endothelial C5b-9
deposits with control sera (mean 6 SE). °P , .001 vs control serum; $P , .001 vs case 7 pre-Ecu.
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them unsuitable for clinical use”37 is consistent with ﬁnding here that
both serum C3 and plasma SC5b-9 levels did not appreciably change
or even increased after eculizumab. Because eculizumab recognizes
the C5b portion of C5,15 it could form with SC5b-9 clinically
inactive complexes with slow plasma clearance. If this is the case,
such complexes would be detected in the SC5b-9 enzyme-linked
immunosorbent assay, rendering SC5b-9 measurement not suit-
able to monitor eculizumab’s therapeutic effect in aHUS. Neither
CH50 was of help to monitor eculizumab effectiveness, because
values measured during treatment did not parallel signs of disease
activity.
On the other hand, we found that normalization of serum-induced
C5b-9 deposits on ADP-activated endothelium paralleled or even
preceded (as in case 5) eculizumab-induced clinical remission. Thus,
the ex vivo test presented here is a tool to monitor eculizumab
efﬁciency and personalize eculizumab therapy. In support of the
above possibility are data showing that measurement of serum-
induced endothelial C5b-9 deposits allowed us to document that the
eculizumab dose initially given to 2 pediatric patients, to prevent
posttransplant recurrence in one (case 5) and during the acute episode
in the other (case 6), was not enough to fully control complement
activation at endothelial level, despite normal plasma SC5b-9
suggesting an efﬁcient complement control inﬂuid phase. Enhancing
the eculizumab dose from 300 to 600 mg in the ﬁrst case and from
600 mg to 900 mg in the second one normalized both ex vivo
endothelial C5b-9 deposits and clinical parameters.
The effectiveness of eculizumab to inhibit complement-mediated
thrombotic microangiopathy13,15 led regulatory agencies in the
United States and Europe to approve this drug for the treatment of
aHUS. However, the extremely high cost of eculizumab (about US
$350 000 per patient per year) and the need of lifelong treatment may
be important limitations to its widespread use in aHUS, even in
relatively high-resource settings. The case of the UK health minister,
who on May 2013 rejected a recommendation from an expert
committee that the drug be “routinely provided nationally” and refused
to fund eculizumab to a woman with aHUS, is paradigmatic.16,17
After that episode, the National Health System published an interim
commissioning policy (NHS England, September 2013 E03/PS
[HSS]/a) deﬁning patients to whom eculizumab treatment will be
provided, pending evaluation and ﬁnal decision by the National
Institute for Health and Care Excellence.
Thus, as highlighted by Tanimoto et al in their letter, “it is crucial
to explore the most appropriate dose, dosage intervals and duration
of treatment to reduce the enormous ﬁnancial burden of eculizumab
therapy.”36 In this regard, our ex vivo test, when performed in
suitably equipped laboratories, could be a helpful tool to adjust the
eculizumab dose and the interval between doses to the minimum
necessary to block complement at the endothelial level, thus avoiding
drug overexposure and waste of money. That this might be the case
is supported here by the 2 adult patients (cases 7 and 8) in whom
treatment could be spaced every 3 and 4 weeks, respectively, with the
support of prospective evaluation of ex vivo C5b-9 deposits on ADP-
activated endothelium, without changes in clinical parameters.
Prospective studies in a larger number of patients are needed to prove
the sensitivity of the ex vivo test proposed here to guide eculizumab
dosage and spacing in aHUS patients, particularly in the presence of
inciting events like infections or pregnancies.
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